The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer
Open Access
- 13 February 2009
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in European Radiology
- Vol. 19 (6), 1347-1357
- https://doi.org/10.1007/s00330-009-1303-z
Abstract
We evaluated the role of 18F-FDG PET/CT for the assessment of response after two cycles of neo-adjuvant chemotherapy (NACT) for breast cancer. Twenty-three women with locally advanced breast cancer were included in this study. Early response to NACT was evaluated after two cycles using clinical examination, CT, and 18F-FDG PET/CT. Final histopathology following surgery after six cycles of NACT served as reference. Baseline PET/CT demonstrated a total of 26 lesions in 23 patients. The size of the primary tumor ranged from 1.90 cm to 11.60 cm, and the maximum value of the standardized uptake value of FDG (SUVmax) ranged from 3.6 to 38.6 (mean, 11.7). Post-chemotherapy PET/CT examinations were done after two cycles of NACT. The size of the primary tumor on follow-up PET/CT examinations ranged from 0.0 cm to 7.6 cm, and SUVmax ranged from 0.0 to 12.0 (mean, 3.96). On clinical, CT, and PET/CT examinations, 50% reduction in the parameters was taken as the cutoff value to differentiate between responders and non-responders. Post-NACT PET/CT demonstrated that 16 patients were responders and 7 non-responders. Among 16 responders on PET/CT scan, 14 were true positive and 2 were false positive when compared with histopathology. Among seven non-responder patients, six were true negative, and one was false negative. The sensitivity, specificity, and accuracy of PET/CT in detecting responders were 93%, 75%, and 87%, respectively. In conclusion, 18F-FDG PET/CT can differentiate responders from non-responders with high accuracy after two cycles of NACT in patients with LABC.Keywords
This publication has 29 references indexed in Scilit:
- Estimates of the cancer incidence and mortality in Europe in 2006Annals Of Oncology, 2007
- Monitoring primary breast cancer throughout chemotherapy using FDG-PETBreast Cancer Research and Treatment, 2006
- Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survivalCancer, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy?European Journal of Cancer, 1995
- Primary chemotherapy in surgically resectable breast cancerCA: A Cancer Journal for Clinicians, 1995
- Positron emission tomography: 2-deoxy-2-Z18F]-fluoro-d-glucose uptake in locally advanced breast cancersEuropean Journal of Surgical Oncology, 1995
- Breast cancer: Chemotherapy in the treatment of advanced diseaseEuropean Journal of Cancer, 1993
- CARCINOMA OF THE BREAST*Annals of Surgery, 1943
- CARCINOMA OF THE BREASTAnnals of Surgery, 1942